This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Adler, A. S. Articles by Chang, H. Y. Search for Related Content PubMed PubMed Citation Articles by Adler, A. S. Articles by Chang, H. Y.

CSN5 Isopeptidase Activity Links COP9 Signalosome Activation to Breast Cancer Progression

¹ Program in Epithelial Biology and ² Cancer Biology Program, Stanford University School of Medicine, Stanford, California and ³ Department of Anatomy, University of California, San Francisco, California

Requests for reprints: Howard Y. Chang, Stanford University School of Medicine, 269 Campus Drive, CCSR 2155, Stanford, CA 94305. Phone: 650-736-0306; Fax: 650-723-8762; E-mail: howchang{at}stanford.edu.

CSN5 has been implicated as a candidate oncogene in human breast cancers by genetic linkage with activation of the poor-prognosis, wound response gene expression signature. CSN5 is a subunit of the eight-protein COP9 signalosome, a signaling complex with multiple biochemical activities; the mechanism of CSN5 action in cancer development remains poorly understood. Here, we show that CSN5 isopeptidase activity is essential for breast epithelial transformation and progression. Amplification of CSN5 is required for transformation of primary human breast epithelial cells by defined oncogenes. The transforming effects of CSN5 require CSN subunits for assembly of the full COP9 signalosome and the isopeptidase activity of CSN5, which potentiates the transcriptional activity of MYC. Transgenic inhibition of CSN5 isopeptidase activity blocks breast cancer progression evoked by MYC and RAS in vivo. These results highlight CSN5 isopeptidase activity in breast cancer progression, suggesting it as a therapeutic target in aggressive human breast cancers. [Cancer Res 2008;68(2):506–15]